Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

20%

Ph phase_4

40%

Ph not_applicable

20%

Ph early_phase_1

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

1(20.0%)

Phase 3Large-scale testing

1(20.0%)

Phase 4Post-market surveillance

2(40.0%)

N/ANon-phased studies

1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Other(1)

Detailed Status

Completed3

unknown1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (20.0%)

Phase 31 (20.0%)

Phase 42 (40.0%)

N/A1 (20.0%)

Trials by Status

unknown120%

completed360%

withdrawn120%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_3

Nebulized Dexmedetomidine Versus Neostigmine/Atropine in Postdural Puncture Headache

NCT04910477

completednot_applicable

Sugammadex and Cognitive Function

NCT02419352

unknownearly_phase_1

Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium

NCT03328312

withdrawnphase_4

Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)

NCT02410590

completedphase_4

Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade

NCT02215382

Clinical Trials (5)

Showing 5 of 5 trials

NCT04910477Phase 3

Nebulized Dexmedetomidine Versus Neostigmine/Atropine in Postdural Puncture Headache

Completed

NCT02419352Not Applicable

Sugammadex and Cognitive Function

Completed

NCT03328312Early Phase 1

Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium

Unknown

NCT02410590Phase 4

Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)

Withdrawn

NCT02215382Phase 4

Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5